Given that previous studies have demonstrated aberrant XOR overexpression and markedly increased oxidative stress in MASLD patients [14,15], XOR has emerged as a promising potential therapeutic target for MASLD. The gene discussed is XDH; the disease is metabolic dysfunction-associated steatotic liver disease.